Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Registry of management and outcomes of bleeding complications in patients treated with NOACs
NL-OMON44969Active, not recruiting
- Sponsor
- Amsterdam University Medical Center
- Start
- Jan 2015
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Open-label trial of dabigatran, rivaroxaban, apixaban, edoxaban and prothrombin complex concentrate, human in Atrial fibrillation (AFib), deep vein thrombosis (DVT) and pulmonary embolism (PE) (4 arms), sponsored by Amsterdam University Medical Center. Primary endpoints: Successful clinical outcome of bleeding and Major bleeding within 30 days after emergency invasive procedure. Started Jan 2015; status: active, not recruiting.
02
Drugs
dabigatranrivaroxabanapixabanedoxabanprothrombin complex concentrate, human
03
Conditions
Atrial fibrillation (AFib)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON44969.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON44969.